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Abstract 
Background: The prevalence of subclinical atherosclerosis and the main predictors of progression of this condition in 
patients undergoing peritoneal dialysis (PD) have been insufficiently investigated. 
Objectives and method: Following a prospective, multicenter, observational design, we studied 237 patients who 
were treated with PD for ≥3 months, without any clinical background of cardiovascular (CV) disease. Our objectives 
were the following: (1) to investigate the prevalence of subclinical atherosclerosis, as compared to a control group of 
age- and sex-matched healthy individuals, and (2) to disclose PD technique-related predictors of progression of 
disease during a 24-month follow-up period. We used vascular ultrasound for characterization of subclinical 
atherosclerotic disease. 
Main results: A total of 123 patients (51.9%) vs. 79 controls (33.5%) presented ≥1 carotid plaque, and 114 patients 
(48.3%) vs. 72 controls (30.5%) ≥1 femoral plaque, at baseline evaluation (p < 0.0005). Progression of disease, either 
in clinical or ultrasound (new plaques) terms, affected 62.6% of patients. Multivariate analysis identified age, carotid 
intima-media thickness, presence of ≥1 carotid plaque, and serum levels of 25OH vitamin D and C-reactive protein 
(CRP) at baseline as independent correlates of progression of atherosclerotic disease. On the contrary, PD technique-
related variables did not show any association with this outcome. 
Conclusions: Atherosclerotic vascular disease is frequent among asymptomatic patients undergoing PD. Older age, 
pre-existent disease (assessed by vascular ultrasound), and serum levels of 25OH vitamin D and CRP are independent 
markers of the progression of this condition. These findings may contribute to improve identification of 
subpopulations with a high risk of CV events, deserving intensified measures of prevention. 
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Introduction  
Cardiovascular (CV) disease (CVD) represents the main cause of mortality among patients with end-
stage renal disease (ESRD). This disorder has a complex pathogenesis and results from the interaction of 
many traditional and non-traditional CV risk factors, which are very prevalent, in these patients. These 
factors are related to preexistent comorbidities, adverse consequences of the chronic kidney disease 
(CKD) environment, and undesired effects of renal replacement therapies (RRTs) [1]. 
 
Atherosclerosis is a primary contributor to CVD in patients with ESRD [1]. A significant proportion 
of affected individuals have a background of atherothrombotic events before RRT is initiated, and many 
others will undergo fatal or nonfatal events of this type during follow-up. Consequently, prevention of the 
progression of atherosclerotic disease is an essential part of the management of patients on dialysis. 
Subjects with a back-ground of previous CV events, and also those who ac-cumulate a high burden of CV 
risk factors, represent obvious targets for intensified preventive measures. Detection of subclinical 
atherosclerosis may help to re-fine identification of individuals with an increased CV risk. High-
resolution vascular ultrasonography (vUS) is a reliable and relatively simple tool for the study of 
arteriosclerotic vascular disease. Increased carotid intima-media thickness (cIMT) and the presence of 
calcified and non-calcified plaques are strong predictors of CV events in the general population [2–5], 
and have been claimed to portend similar outcomes in patients with ESRD [6–8]. 
 
The impact of the different modalities of dialysis on the progression of atherosclerotic vascular 
disease is a matter of controversy. In particular, peritoneal dialysis (PD) associates some pro-atherogenic 
features [9], which may compromise the long-term CV outcome of affected patients [10]. vUS could 
contribute to characterize the atherosclerotic burden of PD patients, but available in-formation is based on 
cross-sectional comparisons with hemodialysis patients, with inconclusive results [11–13]. A longitudinal 
approach could be more effective to de-fine the main risk factors for progression of atherosclerotic 
vascular disease in this population but, to our knowledge, this approach has not been undertaken so far. 
 
We present the results of a prospective, multicenter, observational study, oriented to (1) investigate 
the prevalence of subclinical atherosclerotic vascular disease in asymptomatic patients undergoing 
chronic PD, and (2) identify clinical correlates of progression of this disorder, with a particular focus on 
PD technique-related factors, in these patients. 
Method  
General study design and participants  
The NEFRONA project is a Spanish multicenter, observational, prospective study, designed to 
investigate the atherosclerotic bur-den of patients in different stages of CKD, including relatively large 
samples of patients with ESRD treated with dialysis. A large control group of individuals without CKD is 
also available. The general design and objectives of the project have been reported in detail elsewhere 
[14–16]. The study was able to recruit 2,445 CKD patients, 18–75 years of age, from 81 different Spanish 
hospitals, between October 2010 and June 2012. Remarkably, NEFRONA aimed to investigate only 
patients without overt atherosclerotic disease at the start of follow-up. Consequently, candidates with a 
background of previous coronary, cerebrovascular, peripheral vascular, or any other type of CV event 
were not eligible. 
 
For the present study, we investigated all the patients treated with PD who were recruited for 
NEFRONA. The study population comprised 237 patients prevalent on PD (previous follow-up ≥ 3 
months under this modality of RRT) from 37 different units, distributed all over Spain. A control group, 
composed of 237 age- and sex-matched subjects without CKD, was built for comparisons. The study had 
a 2-fold objective. First, we aimed to investigate the prevalence and extension of subclinical 
atherosclerotic disease in PD patients as compared with healthy controls. For this purpose, a thorough 
base-line evaluation was performed. Second, we focused our analysis on disclosing markers of 
progression of subclinical disease in PD patients, for which a follow-up visit was scheduled 24 months 
after the initial evaluation. Patients (n= 8) who had significant (>70%) stenotic carotid plaques ( n= 4; 
vUS) or an ankle-brachial index (ABI) <0.7 ( n= 6) at baseline evaluation ( vide infra) were considered to 
present clinically significant vascular disease, and did not undergo further analysis. We also excluded 
from longitudinal analysis those patients who received a renal allograft, who were lost to follow-up, or 
who died for non-CV reasons within 24 months after the baseline visit. Subjects who suffered a CV event 
during the aforementioned period were considered for longitudinal analysis (see below), but did not 
undergo the scheduled 24-month visit (vUS). 
 
The study complied with the principles of the Declaration of Helsinki. The protocol was approved by 
the Institutional Commit-tee of each participating center, and written informed consent was obtained from 
all participants. 
Collection and management of clinical and biochemical data  
At the time of recruitment, we gathered information about cur-rent health status, medical history, 
preexistent CV risk factors, and drug therapies. A general physical examination was performed, and ABI 
was estimated, as previously described [17]. Blood samples were retrieved for biochemical parameters 
(Table 1) as close as possible to the baseline visit, and always within 3 months of the baseline vUS study. 
Biochemical determinations were performed, for the most part, in the participating centers, with the help 
of autoanalyzers. Parathyroid hormone levels were standardized using a conventional conversion method 
[18]to compensate for inter-method variability between different centers. Determinations of high-
sensitivity C-reactive protein (CRP; Immunoturbidimetry, Roche Hitachi, Modular Analytics, 
Indianapolis, IN, USA) and 25-hydroxy-vitamin D (ELISA, IDS, Tyne and Wear, UK) levels were 
carried out in a central laboratory to avoid variability among methods. Residual kidney function 
glomerular filtration rate (GFR) was estimated as the mean of urea and creatinine renal clearances. 
 
vUS explorations were performed by 3 itinerant teams, who also performed anthropometric and ABI 
estimations, and retrieved blood samples. 
Table 1. Main baseline characteristics of the study population and control group 
 PD patients Controls p value 
    
 237 237  
Age, years 51.2 (13.7) 51.4 (12.9) 0.87 
Gender, male/female, % 58.1/41.9 58.1/41.9 1.00 
Diabetes mellitus, % 43 (18.1) 35 (14.8) 0.38 
Tobacco (nonsmoker/former/smoker), % 43.2/37.7/19.1 44.5/38.6/16.9 0.84 
Systolic blood pressure, mm Hg 143.9 (23.8) 130.4 (16.3) 0.0005 
Diastolic blood pressure, mm Hg 85.6 (13.5) 78.4 (9.1) 0.0005 
Pulse pressure, mm Hg 58.4 (17.9) 52.0 (12.1) 0.0005 
Body mass index, kg/m2 26.7 (4.9) 28.1 (4.6) 0.001 
Total cholesterol, mg/dL 180.1 (42.8) 195.7 (35.0) 0.005 
HDL cholesterol, mg/dL 49.4 (14.9) 52.8 (14.9) 0.02 
LDL cholesterol, mg/dL 103.6 (34.1) 120.1 (31.4) 0.0005 
Triglycerides, mg/dL 123 (35–419) 94 (31–662) 0.001 
Hemoglobin, g/dL 12.2 (1.4) 14.4 (1.5) 0.0005 
Plasma albumin, g/dL 3.8 (0.5) 4.4 (0.3) 0.0005 
C-reactive protein, mg/dL 0.21 (0.0–13.1) 0.14 (0.0–5.6) 0.001 
Serum calcium, mg/dL 9.2 (0.7) 9.4 (0.4) 0.0005 
Serum phosphate, mg/dL 5.1 (1.2) 3.5 (0.6) 0.0005 
Serum 25OH vitamin D, ng/mL 12.8 (5.5) 20.6 (8.4) 0.0005 
Serum 1,25OH vitamin D, pg/mL 7.7 (4.8) 33.0 (14.4) 0.0005 
Uric acid, mg/dL 6.0 (1.2) 5.1 (1.4) 0.0005 
Parathyroid hormone, pg/mL* 277.5 (214.2) – – 
    
 
Figures denote mean values (SD) or n(%). Triglycerides and C-reactive protein presented as median values (range).  
* Normalized for assay. 
 
 
  
Vascular Ultrasound  
B-mode ultrasound of the carotid and femoral arteries was per-formed using the Vivid BT09 device 
(General Electric Instruments, Chicago, IL, USA), with the help of 6–13 MHz broadband linear array 
probes. The measurement of IMT and the search for atheromatous plaques was performed by a unique 
reader in a blinded fashion, using the semi-automatic software EchoPAC Dimension (General Electric 
Healthcare, Chicago, IL, USA). We previously assessed the quality of the reading and the intraobserver 
variability, using a sample of 20 individuals in whom estimations were per-formed 3–5 times at different 
days. A kappa coefficient of 1 was obtained, indicating optimal intraobserver reliability. 
 
Bilateral US imaging was performed with the subjects in a supine position. For carotid US, the head 
was turned 45° contra-lateral to the side of the probe, and cIMT was measured in the last centimeter of 
the far wall of the common carotid artery, the bifurcation section, and finally, the first centimeter of the 
internal carotid artery. Measurements were made in plaque-free arterial segments. The presence of 
atheromatous plaques in each of the mentioned points was defined by an IMT ≥ 1.5 mm protruding to the 
lumen, following the recommendations of the ASE Consensus Statement [18] and the Mannheim cIMT 
Consensus report [19]. 
Study Variables  
For cross-sectional comparisons between PD patients and healthy controls, the main study variables 
were cIMT and the presence of atheromatous plaques in the carotid and femoral territories. For the latter 
purpose, we created plaque scores, which resulted from the addition of the number of points scrutinized 
(6 for the carotid territories, including common, bifurcation, and internal carotid arteries on each side, and 
4 for the femoral territories, including common and superficial femoral arteries on each side) in which at 
least 1 plaque was detected. Thus, the score ranged between 0 (no plaques) and 6 (all sites examined with 
plaque) in the carotid territories, and between 0 and 4 in the fem-oral territories. 
 
For the longitudinal study, the main outcome variable was progression of atherosclerotic disease, 
arbitrarily defined as 1 or 2 of the following: appearance of, at least, a new carotid plaque in the 24-month 
visit (vUS), or significant (demanding in-center evaluation or management) CV event during the 24-h 
follow-up period. Only carotid, but not femoral plaques were used to build this score, to facilitate 
comparability with other studies based on vUS. The study had an exploratory design, meaning that we 
considered as study variables all those collected at baseline. However, we focused on some with a 
specific interest in PD patients, including time on dialysis, blood pressure levels, GFR, peritoneal 
transport characteristics, conditions of prescription, lipid profiles, serum vitamin D levels, plasma 
albumin levels, and bone mineral disease markers. Peritoneal transport was characterized from the D/P 
quotient of creatinine at 240’ at the time of initiation of the study, according to the local standards of each 
participating center. 
Data Analysis  
Numeric variables are presented as mean values with SD, except those with a markedly abnormal 
distribution (median with range). Categorized variables are presented as absolute numbers (%). Main 
univariate comparisons were produced by means of Student t test, ANOVA, Mann–Whitney test, and χ2 
distribution. The Spearman’s correlation coefficient was used to analyze correlations among numerical 
variables. Statistical significance was de-fined by a p value <0.05. 
 
We used stepwise logistic regression analysis to investigate factors associated with the progression of 
atherosclerotic disease. As previously stated, all the recorded baseline variables were considered for 
analysis. Only variables with a univariate association to progression with a p value <0.10, as also those 
with a specific interest in PD patients (vide supra) were explored during multivariate analysis. 
Furthermore, we constructed 2 different multivariate approaches, first focusing on clinical and laboratory 
variables (Model 1), and then introducing objective baseline estimations of vascular disease (baseline 
cIMT, baseline number of plaques, pulse pressure, and ABI; Model 2). Only first-degree interaction terms 
were scrutinized. 
 
The SPSS 19.0 software was used for data analysis.  
Results  
Baseline Data  
The essential baseline characteristics of the study group and matched controls are presented in Table 
1. With the notable exceptions of total and LDL cholesterol levels, the CV risk profile was more 
unfavorable in PD patients than in controls. The essential conditions of prescription for patients are 
displayed in Table 2. 
Table 2. Main baseline dialysis- and prescription-related variables in PD patients 
  
Time on dialysis, months 19.9 (13.7; range 3–90) 
Category of small solute transport (S/SA/FA/F), % 9.4/26.5/52.6/11.5 
Modality of PD (CAPD/automated PD), % 43.6/56.4 
Volume of dialysate, mL/24 h 9,232 (8,504) 
Type of PD solution (high/low in GDP), % 62/175 (26.2/73.8) 
Icodextrin for long dwell, % 116 (49.2) 
Residual kidney function (GFR), mL/min 5.8 (5.2) 
Diuresis, mL/24 h 1,251 (1,200) 
Peritoneal, Kt/V 1.48 (1.44) 
Total, Kt/V 2.52 (2.43) 
Daily ultrafiltration, mL/24 h 759 (714) 
Treatment with antihypertensives, % 214 (90.3) 
Treatment with RAAS antagonists, % 148 (62.4) 
Treatment with statins, % 137 (57.8) 
Treatment with antiplatelet drugs, % 54 (22.8) 
Treatment with vitamin D or analogues (any type), % 120 (50.6) 
  
 
Figures denote mean values (SD) or n(%). 
S, slow; SA, slow average; FA, fast average; F, fast; GDP, glucose degradation products; RAAS, 
renin-angiotensin-aldosterone system. 
 
PD patients presented a different ABI pattern, when compared with controls (Table 3). Both 
abnormally low and high values were more frequent in the former group. As refers to baseline arterial US 
findings, mean cIMT was similar in patients and controls (Table 3). On the contrary, both carotid and 
femoral plaques were significantly more prevalent in PD patients (Table 3). 
Table 3. Baseline markers of atherosclerotic vascular disease 
 Patients Controls p value 
    
Ankle-brachial index 1.07 (0.25) 1.03 (0.10) 0.052 
Distribution   0.0005 
<0.70 6 (2.6) 0 (0)  
0.70–0.90 27 (11.4) 20 (8.4)  
0.91–1.40 194 (81.9) 217 (91.6)  
>1.40 10 (4.2) 0 (0)  
Carotid intima-media thickness, mm 0.68 (0.13) 0.69 (0.14) 0.86 
Number of patients with at least one carotid plaque, % 123 (51.9) 79 (33.5) 0.0005 
Plaque score for carotid territories 1.16 (1.46) 0.64 (1.08) 0.0005 
Number of patients with at least one femoral plaque, % 114 (48.3) 72 (30.5) 0.0005 
Plaque score for femoral territories 0.93 (1.17) 0.50 (0.86) 0.0005 
    
 
Figures denote mean values (SD) or n(%). 
 
 
  
Among patients, the baseline carotid plaque score correlated with age (r = 0.50, p < 0.0005, 
Spearman), diabetes (1.9 ± 1.5 vs. 1.0 ± 1.4 in non-diabetics, p < 0.0005), pulse pressure (r = 0.18, p = 
0.017), body mass index (r = 0.15, p = 0.018), plasma albumin (r = –0.21, p = 0.001), and se-rum levels 
of 25OH vitamin D (r = –0.17, p = 0.009) and CRP (r = 0.18, p = 0.006; all other variables presented in 
Tables 1 and 2 ; not significant). 
Follow-Up  
Twenty-eight PD patients (11.8%) suffered at least 1 CV event, and 12 of them died due to CV 
reasons, during the 24-month follow-up study period. These patients were considered for analysis of 
vascular disease progression, but not of plaque progression (vUS). According to the study protocol, we 
excluded 8 patients (3.4%) from longitudinal analysis who died of non-CV reasons, 5 patients (2.1%) 
who were lost to follow-up, and 119 patients (50.2%) who received a kidney allograft during the 24-
month follow-up period. Overall, 99 patients were available for the analysis of predictors of disease 
progression, including the 28 who suffered at least 1 CV event during follow-up, and 71 more individuals 
who completed the 24-month vUS assessment. 
 
As compared with patients included in the follow-up analysis, excluded patients were younger (48.9 ± 
12.8 vs. 53.8 ± 14.1 years, p = 0.005), presented lower serum levels of CRP (0.16 mg/dL [median range 
0.02–5.29] vs. 0.33 mg/dL [0.02–13.17, p = 0.001, Mann–Whitney] and had marginally lower values of 
pulse pressure [56.2 ± 16.9 vs. 60.7 ± 18.7, p = 0.056] and number of plaques [carotid and femoral] at 
baseline [1.8 ± 2.3 vs. 2.4 ± 2.2, p = 0.078]; all other variables quoted in Tables 1 and 2 not significant). 
 
When only subjects with baseline and 24-month vUS evaluation were considered (n = 71), 12 patients 
(17.4%) had an increase of >0.1 mm in the mean cIMT between both assessments. Moreover, 34 patients 
(47.9%) presented one (n = 24, 33, 8%) or more (n = 10, 14.1%) new carotid plaques, and 37 patients 
(52.1%) presented one (n = 25, 35.1%) or more (n = 12, 16.9%) new femoral plaques. No patient 
appeared to develop severely stenotic (>70%) carotid plaques on follow-up vUS. 
 
Table 4 shows the distribution of baseline variables, according to disease progression during follow-
up. The multivariate, clinical model for baseline predictors of dis-ease progression (Table 5, Model 1) 
identified older age, lower serum levels of 25OH vitamin D, and higher serum levels of CRP as 
independent correlates of this outcome. The inclusion of objective estimations of baseline vascular 
disease resulted in 2 different predictive models (Table 5). Model 2a included carotid plaques at baseline 
as the most consistent predictor of disease progression, while serum levels of 25OH vitamin D and CRP 
persisted as independent predictors of disease progression. Model 2b, which was slightly less accurate, 
identified baseline mean cIMT as an alternative, consistent predictor of the main outcome. We did not 
detect any significant interaction term between variables in either model. While the association between 
CRP levels and progression of disease was largely restricted to patients in the higher tertile for this factor, 
the association of 25OH vitamin to CV disease progression was essentially linear, without apparent cutoff 
points. Remarkably, neither diabetes nor treatment with statins, renin-angiotensin-aldosterone system 
(RAAS) antagonists nor vitamin D (any type) were identified as independent markers of disease 
progression after controlling for age, baseline carotid plaque score, or baseline cIMT 
  
Table 4. Correlation between main baseline variables and atherosclerotic disease progression: univariate analysis 
 Progession (n = 62) No progession (n = 37) p value 
    
Age, years 57.1±11.8 48.4±14.7 0.002 
Gender, male/female, % 64.5/35.5 54.1/45.9 0.35 
Diabetes mellitus, % 27.4 8.1 0.021 
Tobacco (non-smoker/former/smoker), % 37.1/43.5/19.4 40.5/43.2/16.2 0.90 
Systolic blood pressure, mm Hg 149.1±23.5 143.7±23.7 0.28 
Diastolic blood pressure, mm Hg 87.2±13.8 86.9±11.8 0.92 
Pulse pressure, mm Hg 61.9±18.8 56.8±17.0 0.18 
Body mass index, kg/m2 26.7±4.4 26.7±6.2 0.96 
Total cholesterol, mg/dL 187.2±52.4 183.5±40.3 0.67 
HDL cholesterol, mg/dL 48.2±15.5 51.8±16.2 0.28 
LDL cholesterol, mg/dL 108.0±40.7 106.2±27.5 0.82 
Triglycerides, mg/dL 134 (50–376) 121 (35–250) 0.85 
Hemoglobin, g/dL 12.0±1.6 12.1±1.4 0.80 
Plasma albumin, g/dL 3.7±0.5 3.8±0.5 0.74 
Serum C-reactive protein, mg/dL 0.42 (0.05–13.1) 0.15 (0.03–5.5) 0.003 
Serum calcium, mg/dL 9.0±0.6 9.1±0.9 0.59 
Serum phosphate, mg/dL 5.1±1.4 5.0±1.0 0.79 
Serum 25OH vitamin D, ng/mL 11.9±5.6 14.6±5.0 0.019 
Serum 1,25OH vitamin D, pg/mL 7.8±3.7 7.2±2.8 0.37 
Uric acid, mg/dL 6.2±1.2 5.6±1.0 0.015 
Parathyroid hormone, pg/mL 303.6±312.7 258.2±182.0 0.42 
Ankle-brachial index 1.13±0.35 1.10±0.25 0.59 
Baseline cIMT, mm 0.70±0.13 0.60±0.11 0.0005 
Baseline carotid plaque score 1.71±1.33 0.57±1.11 0.0005 
Baseline femoral plaque score 1.11±1.13 0.69±1.11 0.033 
GFR, mL/min 5.9±5.8 6.2±4.2 0.80 
Kt/V 2.58±0.69 2.36±0.53 0.09 
Volume of dialysate, mL/24 h 9,399±4,109 8,597±4,112 0.47 
PD solutions rich in GDP, % 30.6 24.3 0.50 
Icodextrin for long dwell, % 54.8 45.9 0.39 
PD ultrafiltration, mL/24 h 812±668 729±663 0.55 
Time on dialysis, months 19.7±20,8 15.4±12.8 0.26 
Peritoneal transport (slow/slow aver age/fast average/fast), % 6.5/21.0/61.3/11.3 10.8/24.3/40.5/24.3 0.81 
Treatment with statins, % 56.5 59.5 0.77 
Treatment with RAAS inhibitors, % 59.7 64.9 0.61 
Treatment with vitamin D or analogues, % 45.2 48.6 0.74 
    
 
cIMT, carotid intima-media thickness; GDP, glucose degradation products; RAAS, renin-angiotensin-aldosterone system. 
Numerical variables presented as mean (SD), except triglycerides and C-reactive protein (median with range). Categorized variables 
presented as %. 
  
Table 5. Predictors of progression of atherosclerotic disease: multivariate analysis 
 OR 95% CI p value 
    
Model 1 (only clinical and laboratory variables)    
Χ2 20.39, R2 (Cox–Snell) 0.19, –2 log likelihood 106.6    
Age, per years 1.05 1.01–1.08 0.026 
Plasma C-reactive protein (ref. lower tertile)    
Median tertile 1.31 0.35–4.96 0.70 
Higher tertile 3.30 1.03–10.52 0.044 
Serum 25OH vitamin D, per ng/mL 0.90 0.82–0.98 0.020 
    
Model 2a (with baseline carotid plaque)    
Χ2 28.7, R2 (Cox–Snell) 0.29, –2 log likelihood 98.3    
Presence of baseline plaque (ref. no) 7.07 2.37–21.06 0.0005 
Plasma C-reactive protein (ref. lower tertile)    
Median tertile 1.21 0.37–2.94 0.81 
Higher tertile 3.28 1.06–11.16 0.024 
Serum 25OH vitamin D, per ng/mL 0.90 0.83–0.97 0.027 
    
Model 2b (with baseline intima-media thickness)    
Χ2 27.4, R2 (Cox–Snell) 0.27, –2 log likelihood 90.9    
Carotid intima-media thickness (ref. lower tertile)    
Median tertile 6.24 1.68–23.32 0.006 
Higher tertile 7.48 2.18–25.63 0.001 
Plasma C-reactive protein (ref. lower tertile)    
Median tertile 0.95 0.25–3.04 0.80 
Higher tertile 3.15 0.99–10.93 0.056 
Serum 25OH vitamin D, per ng/mL 0.88 0.80–0.97 0.016 
    
 
Stepwise logistic regression analysis. Outcome variable: progression of atherosclerosis during follow-up (either appearance of at 
least one new carotid plaque or cardiovascular event during the 24-month follow-up period). All other variables (clinical, laboratory, 
treatment-related or PD-related) not significant. 
Discussion  
The results of our study show that atherosclerotic disease is very prevalent in asymptomatic patients 
treated with PD. Moreover, the disease is progressive in a high proportion of patients, even after a 
relatively short follow-up of 24 months. The proportion of patients suffering CV events (11.8%) or 
developing new carotid (47.9%) or fem-oral (52.1%) plaques during the 24-month follow-up was 
remarkable, considering that only patients without overt CV disease at baseline were included in the 
analysis. Similar findings have been reported for patients with CKD [20] and unselected populations on 
chronic dialysis [21]. These observations are worrisome, but not totally unexpected, given the high 
burden of traditional and non-traditional CV risk factors supported by these patients, resulting in elevated 
rates of CV mortality [1]. Patients undergoing PD are not an exception to this rule [9]. In fact, some 
factors specifically associated to this technique, including volume overload, peritoneal loading with 
dialysis solutions rich in glucose and glucose degradation products, and a continuous peritoneal leak of 
proteins and other macromolecules, may contribute to the well-known late surge in the CV risk of these 
patients [10]. 
 
CV events represent the most direct way to assess progression of CV disease. However, detecting this 
evolution before these events occur may permit a more accurate and profitable stratification of risk, 
helping to define subsets who could be a subject of intensified prevention measures. This strategy 
demands both tight monitoring and management of modifiable risk factors and a systematic use of 
reliable estimators of asymptomatic CV disease, including echocardiography and vUS. Regarding the 
latter, cIMT and the presence of carotid plaques are well standardized tools [18, 19], and have 
demonstrated to be highly predictive of CV risk, both in the general population [2–5]and in the particular 
case of patients with ESRD [7, 8, 21]. 
 
Comparing the significance of different markers of progression of subclinical CV disease in patients 
with ESRD treated with PD is a difficult task, due to the large set of factors with a potential effect on this 
outcome [9]. In our study, age and the presence of arterial disease (either increased cIMT or presence of 
plaques) at baseline were most consistent predictors of the risk of disease progression. A high 
inflammatory score (as estimated from CRP) also portended a significant risk of disease progression, in 
agreement with previous studies [22]. On the other hand, baseline serum levels of 25OH vitamin D, but 
not 1,25OH vitamin D, kept an independent, significant association with the risk of progression of CV 
dis-ease. The consistency of this association was remarkable and agrees with previous studies, showing 
that low se-rum vitamin D levels portend mortality, and more specifically CV outcomes, both in the 
general population [23, 24]and in patients with different stages of CKD [7, 20, 25–28], including those 
treated with PD [29, 30]. However, the significance of this association still needs some clarification. For 
instance, it is unclear if the association is linear or if, alternatively, CV risk is restricted to patients with 
very low levels of this hormone [25, 27, 28]. The capacity of treatment with native vitamin D or its 
derivatives to improve CV outcomes of vitamin D-deficient patients is another matter of controversy [24, 
28, 31, 32–37]. 
 
The mechanisms by which vitamin D is protective for the CV system have been a subject of great 
interest in the last years, and represent a good example of the pleiotropic effects of this hormone. First, 
vitamin D may preserve endothelial function by different mechanisms, which include direct stimulation 
of NO synthetase, modulation of angiogenesis, downregulation of inflammatory damage, protection 
against oxidative stress, and regulation of endothelium-derived contracting factors [23]. Vitamin D may 
also exert beneficial effects at the level of the vessel wall, including regulation of the proliferation, 
migration and stability of vascular smooth muscle cells, and modulation of fibrosis. Local regulation of T 
lymphocytes and macrophage function at the level of the vessel wall may represent another mechanism of 
vascular protection by vitamin D [38]. On the contrary, the evidence regarding the role of this factor in 
the regulation of vascular calcification is more controversial [23] although in the particular case of 
patients with CKD, there are some data linking vitamin D deficiency with progression of coronary 
calcification [25]. On the other hand, vitamin D may also exert some indirect effects on the genesis and 
progression of atherosclerosis. For instance, low levels of this hormone have been associated with 
defective insulin secretion, insulin resistance, dyslipidemia, and overactivity of the RAAS system [23]. 
All the potential consequences of vitamin D deficiency may be particularly relevant in PD patients, who 
present very low levels of this vitamin, not only when compared with normal individuals, but also with 
patients on earlier stages of CKD or those treated with hemodialysis [30].  
 
Some negative findings in our study may deserve comment. For instance, diabetes was a significant 
correlating factor of atherosclerotic disease at baseline, and portended progression of the condition on 
univariate (Table 4), but not on multivariate analysis, which could be unexpected. The explanation for 
this circumstance is unclear, but the limited statistical power of the study may have obscured the role of 
this factor. On the other hand, most PD-related variables did not show any association with progression, 
suggesting that these factors may not be very influential, at the time of predicting patients’ outcomes. We 
did not record data on peritoneal protein leak for this study. Peritoneal protein excretion has been linked 
to general and CV mortality in PD patients [39, 40]. The potential mechanisms underlying this association 
not only include dyslipidemia and the generation of a prothrombotic environment, but also the 
performance of this factor as a surrogate of endothelial dysfunction. Interestingly, global peritoneal 
protein excretion keeps a close correlation with the peritoneal leak of vitamin D-binding protein, although 
several studies have challenged the influence of this factor on serum levels of vitamin D [41, 42]. Finally, 
treatment with statins, RAAS antagonists, or vitamin D did not show an association with disease 
progression. These findings are not unexpected, due to the significant risk of prescription bias, under the 
design of this study. A randomized trial design should be necessary to clarify this question. Treatment 
with statins has been shown to exert a marginal beneficial effect on CV risk in PD patients [43]. 
 
This study has significant limitations. Despite a multicenter design, the number of patients recruited 
may have been insufficient, given the large number of covariables considered. The high number of PD 
dropouts before completing the protocol contributed to this limitation, and may also have introduced a 
selection bias, because a majority of dropouts were due to kidney transplantation. Among the strengths of 
the study, we should mention its longitudinal, prospective, multicenter design, and the quality of data, 
including well designed vUS explorations and a centralized estimation of variables which came out to 
represent main findings of the investigation, including serum levels of vitamin D. 
 
In summary, atherosclerotic vascular disease is very prevalent among asymptomatic patients 
undergoing chronic PD. Moreover, the disease progresses in a high proportion of these patients during 
follow-up. Older age, mean cIMT, or the detection of at least one carotid plaque during baseline vascular 
US screening, and high serum levels of CRP are independent predictors of disease progression. 
Importantly, lower serum levels of 25OH vitamin D consistently portend this outcome. These findings 
may contribute toward improving the identification of subpopulations with a high risk of CV events and 
mortality, deserving intensified measures of prevention. 
Statement of Ethics  
This study was approved by the ethical committees of all the participating centers, and written 
informed consent was obtained from all participants.  
Disclosure Statement  
The authors have no conflicts of interest to declare. 
References 
1. Wanner C, Amann K, Shoji T: The heart and vascular system in dialysis. Lancet 2016; 388: 276–284.  
2. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke Gl, Wolfson SK Jr: Carotid-artery intima and media 
thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study 
Collaborative Research Group. N Engl J Med 1999; 340: 14–22.  
3. Johnsen SH, Mathiesen EB, Joakimsen O, Stensland E, Wilsgaard T, Løchen ML, et al: Carotid atherosclerosis is 
a stronger predictor of myocardial infarction in women than in men: a 6-year follow-up study of 6226 per-sons: 
the Tromsø Study. Stroke 2007; 38: 2873–2880.  
4. Hollander M, Bots ML, Del Sol AI, Koudstaal PJ, Witteman JC, Grobbee DE, et al: Carotid plaques increase the 
risk of stroke and sub-types of cerebral infarction in asymptomatic elderly: the Rotterdam study. Circulation 
2002; 105: 2872–2877.  
5. Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, et al: Carotid intima-media thickness and presence 
or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In 
Communities) study. J Am Coll Cardiol 2010; 55: 1600–1607.  
6. Benedetto FA, Mallamaci F, Tripepi G, Zoccali C: Prognostic value of ultrasonographic measurement of carotid 
intima media thick-ness in dialysis patients. J Am Soc Nephrol 2001; 12: 2458–2464.  
7. Nishizawa Y, Shoji T, Maekawa K, Nagasue K, Okuno S, Kim M, et al: Intima-media thick-ness of carotid artery 
predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2003; 41(3 suppl 1):S76–S79.  
8. Maeda S, Sawayama Y, Furusyo N, Shigemat-su M, Hayashi J: The association between fatal vascular events and 
risk factors for carotid atherosclerosis in patients on maintenance hemodialysis: Plaque number of dialytic 
atherosclerosis study. Atherosclerosis 2009; 204: 549–555.  
9. Krediet RT, Balafa O: Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol 2010; 6: 451–460.  
10. Vonesh EF, Snyder JJ, Foley RN, Collins AJ: Mortality studies comparing peritoneal dialy-sis and hemodialysis: 
what do they tell us? Kidney Int Suppl 2006; 70:S3–S11.  
11. Yilmaz FM, Akay H, Duranay M, Yilmaz G, Oztekin PS, Kosar U, et al: Carotid atherosclerosis and 
cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Clin Biochem 2007; 40: 1361–1366.  
12. Mutluay R, Degertekin CK, Poyraz F, Yılmaz MI, Yücel C, Turfan M, et al: Dialysis type may predict carotid 
intima media thickness and plaque presence in end-stage renal disease patients. Adv Ther 2012; 29: 370–382.  
13. Shi Z, Zhu M, Guan J, Chen J, He Q, Zhang X, et al: Dialysis methods may affect carotid intima-media thickness 
in Chinese end-stage renal disease patients. Ren Fail 2012; 34: 1206–1211.  
14. Junyent M, Martínez M, Borràs M, Coll B, Valdivielso JM, Vidal T, et al: Predicting cardiovascular disease 
morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a 
prospective, multicenter, observational cohort study. BMC Nephrol 2010; 11: 14.  
15. Junyent M, Martínez M, Borrás M, Bertriu A, Coll B, Craver L, et al: [Usefulness of imaging techniques and 
novel biomarkers in the prediction of cardiovascular risk in patients with chronic kidney disease in Spain: the 
NEFRONA project]. Nefrologia 2010; 30: 119–126.  
16. Arroyo D, Betriu A, Martínez-Alonso M, Vi-dal T, Valdivielso JM, Fernández E: Observational multicenter 
study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease 
cohort: baseline data from the NEFRONA study. BMC Nephrol 2014; 15: 168.  
17. La Piedra C, Fernández E, González Casaus ML, González Parra E: [Different biological functions in PTH 
molecules. What are we measuring?] Nefrologia 2008; 28: 123–128.  
18. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al: Use of carotid ultrasound to identify 
subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American 
society of echocardiography carotid intima-media thickness task force. Endorsed by the society for vascular 
medicine. J Am Soc Echocardiogr 2008; 21: 93–111; quiz 189–190.  
19. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al: Mannheim carotid intima-
media thickness and plaque consensus (2004–2006–2011). An update on behalf of the advisory board of the 3rd, 
4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, 
Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 2012; 34: 290–296.  
20. Gracia M, Betriu À, Martínez-Alonso M, Arroyo D, Abajo M, Fernández E, et al: Predictors of subclinical 
atheromatosis progression over 2 years in patients with different stages of CKD. Clin J Am Soc Nephrol 2016; 
11: 287–296.  
21. Benedetto FA, Tripepi G, Mallamaci F, Zoccali C: Rate of atherosclerotic plaque formation predicts 
cardiovascular events in ESRD. J Am Soc Nephrol 2008; 19: 757–763.  
22. Han SS, Ahn JM, Chin HJ, Chae DW, Oh KH, Joo KW, et al: Impact of C-reactive protein and pulse pressure 
evaluated at the start of peritoneal dialysis on cardiovascular events in the course of treatment with peritoneal 
dialysis. Perit Dial Int 2010; 30: 300–310.  
23. Kassi E, Adamopoulos C, Basdra EK, Papavassiliou AG: Role of vitamin D in atherosclerosis. Circulation 2013; 
128: 2517–2531.  
24. Kunadian V, Ford GA, Bawamia B, Qiu W, Manson JE: Vitamin D deficiency and coronary artery disease: a 
review of the evidence. Am Heart J 2014; 167: 283–291.  
25. de Boer IH, Kestenbaum B, Shoben AB, Mi-chos ED, Sarnak MJ, Siscovick DS: 25-hy-droxyvitamin D levels 
inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol 2009; 15: 1805–
1812.  
26. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, et al: Vitamin D levels and patient outcome in 
chronic kidney dis-ease. Kidney Int 2009; 75: 88–95.  
27. Drechsler C, Verduijn M, Pilz S, Dekker FW, Krediet RT, Ritz E, et al: Vitamin D status and clinical outcomes in 
incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2011; 26: 1024–1032.  
28. Duranton F, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daurès JP, Argilés A: Vitamin D treatment and 
mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol 2013; 37: 239–248.  
29. Wang AY, Lam CW, Sanderson JE, Wang M, Chan IH, Lui SF, et al: Serum 25-hydroxyvi-tamin D status and 
cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr 
2008; 87: 1631–1638.  
30. Gracia-Iguacel C, Gallar P, Qureshi AR, Orte-ga O, Mon C, Ortiz M, et al: Vitamin D deficiency in dialysis 
patients: effect of dialysis modality and implications on outcome. J Ren Nutr 2010; 20: 359–367.  
31. Schnatz PF, Manson JE: Vitamin D and cardiovascular disease: an appraisal of the evidence. Clin Chem 2014; 
60: 600–609.  
32. Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD: Vitamin D supplementation in 
chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized 
controlled trials. Clin J Am Soc Nephrol 2011; 6: 50–62.  
33. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S: Vitamin D status and mortality risk in CKD: a meta-
analysis of prospective studies. Am J Kidney Dis 2011; 58: 374–382.  
34. Kerschbaum J, Vychytil A, Lhotta K, Prischl FC, Wiesholzer M, Machhold-Fabrizii V, et al: Treatment with oral 
active vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal 
dialysis. PLos One 2013; 8:e67836.  
35. Zheng Z, Shi H, Jia J, Li D, Lin S: Vitamin D supplementation and mortality risk in chronic kidney disease: a 
meta-analysis of 20 observational studies. BMC Nephrol 2013; 14: 199.  
36. Miskulin DC, Majchrzak K, Tighiouart H, Muther RS, Kapoian T, Johnson DS, et al: Ergocalciferol 
supplementation in hemodialysis patients with vitamin D deficiency: a randomized clinical trial. J Am Soc 
Nephrol 2016; 27: 1801–1810.  
37. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al: Vitamin D therapy and cardiac 
structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 
2012; 307: 674–684.  
38. Verhave G, Siegert CE: Role of vitamin D in cardiovascular disease. Neth J Med 2010; 68: 113–118.  
39. Perl J, Huckvale K, Chellar M, John B, Davies SJ: Peritoneal protein clearance and not peritoneal membrane 
transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. Clin J Am Soc Nephrol 
2009; 4: 1201–1206.  
40. Pérez-Fontán M, Rodríguez-Carmona A, Barreda D, López-Muñiz A, Blanco-Castro N, García-Falcón T: 
Peritoneal protein transport during the baseline peritoneal equilibration test is an accurate predictor of the 
outcome of peritoneal dialysis patients. Nephron Clin Pract 2010; 116: 104–113.  
41. Joffe P, Heaf JG: Vitamin D and vitamin-D-binding protein kinetics in patients treated with continuous 
ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1989; 9: 281–284.  
42. Prytula A, Wells D, McLean T, Balona F, Gullett A, Knott C, et al: Urinary and dialysate losses of vitamin D-
binding protein in children on chronic peritoneal dialysis. Pediatr nephrol 2012; 27: 643–649.  
43. Lee JE, Oh KH, Choi KH, Kim SB, Kim YS, Do JY, et al: Statin therapy is associated with improved survival in 
incident peritoneal dialysis patients: propensity-matched comparison. Nephrol Dial Transplant 2011; 26: 4090–
4094.  
 
